Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Celecoxib with Paclitaxel/Carboplatin in Stage IIIA NSCLC
NCT00062179Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2003
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celecoxib oral solution in non-small cell lung cancer (NSCLC) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Rates of complete pathological response and/or minimal residual microscopic disease at 3 years. Started Mar 2003; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00062179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062179.